AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 APR 11 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - The use of streptococcal C5a peptidase (SCPB) in a vaccine against group B streptococci (GBS) confers protection from not only GBS but possibly all streptococcal serotypes, according to a report in Infection and Immunity.
SCPB is a surface protein expressed by all streptococcal serotypes tested. Qi Cheng and colleagues at the University of Minnesota proposed its use as a possible carrier protein that could itself confer immunity.
"In this study, we examined the potential of antibody directed against SCPB from a serotype II strain to enhance the capacity of mouse bone marrow macrophages (from primary cultures) and human polymorphonuclear leukocytes (PMNs) in whole blood to kill GBS in vitro," explained Cheng and associates.
They proposed that because clearance of GBS infection probably depends on opsonophagocytic response of such macrophages and human PMNs, pre-opsonizing Streptococcus serotypes with anti-SCPB antibody would strengthen immune response.
Indeed, cultured macrophages and PMNs in whole blood were able to kill Streptococcus serotypes Ia, Ib, II, III, and V that had been pre-opsonized with anti-SCPB antibody more rapidly than GBS that had not been pre-opsonized. This activity was indifferent to serotype, reported Cheng et al.
Furthermore, immunization with SCPB conjugated to capsular polysaccharide type III produced polysaccharide-specific antibodies and promoted clearance of streptococci ...